KYGEVVI
GrowthNDAORALFOR SOLUTIONPriority Review
Approved
Nov 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
KYGEVVI by UCB Pharma is nucleosides, deoxycytidine and deoxythymidine, into skeletal muscle mitochondrial deoxyribonucleic acid (dna). Approved for thymidine kinase 2 deficiency (tk2d) in adults, before 12 years. First approved in 2025.
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYGEVVI is an oral small-molecule combination therapy containing doxecitine and doxribtimine approved by the FDA on November 3, 2025. The mechanism of action and specific indications have not been disclosed in available data, but the oral formulation suggests chronic disease management. The drug represents a novel dual-agent approach, though therapeutic category remains undetermined.
Growth13.8 years to LOE
Product is in launch phase with no established market spending data; commercial teams should expect 12–24 month ramp-up with staffing expansion.
Mechanism of Action
nucleosides, deoxycytidine and deoxythymidine, into skeletal muscle mitochondrial deoxyribonucleic acid (DNA). This action restores mitochondrial DNA copy number in TK2d mutant mice.
Worked on KYGEVVI at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.